Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Neoplasm Metastasis 3Melanoma 3Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Somatostatinoma 2Sarcoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Mesothelioma, Malignant 2Insulinoma 2Glucagonoma 2Gliosarcoma 2Gastrinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Islet Cell 2Brain Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solitary Fibrous Tumor, Pleural 1Primary Myelofibrosis 1Pheochromocytoma 1

Interventions

Sunitinib 2vatalanib 1belzutifan 1Watchful Waiting 1Vorinostat 1Propranolol 1Nivolumab 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangioblastoma × vatalanib × Clear all
NCT00052013 2017-03-06

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Novartis

Phase 2 Completed
11 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡